BioAlliance Pharma Announces DSMB Second Positive Recommendation to Continue its Phase III Clinical Trial With Livatag® in Primary Liver Cancer
5/13/2013 11:13:08 AM
More...
|
BioAlliance Pharma's Sitavig® Receives Market Authorization in the U.S. for the Treatment of Herpes Labialis
4/16/2013 11:08:44 AM
More...
|
BioAlliance Pharma Pursues the Development Plan of Its Loramyc® in Japan Through Its Partner Sosei
3/12/2013 12:05:50 PM
More...
|
BioAlliance Pharma Signs a Collaborative Agreement With One of the Worldwide Leaders in Vaccines for a Vaccine Application of Its Patented Lauriad® Mucoadhesive Technology
2/28/2013 11:59:51 AM
More...
|
BioAlliance Pharma Announces the Forthcoming Extension of Its Phase II Clinical Trial With Validive® in the United States
2/14/2013 11:27:21 AM
More...
|
BioAlliance Pharma Announces the Launch of Oravig® in the United States by Its New Partner, Vestiq Pharmaceuticals
1/7/2013 10:21:27 AM
More...
|
BioAlliance Pharma Receives a Guarantee From Coface to Finance Its Export Activities
1/3/2013 8:55:22 AM
More...
|
BioAlliance Pharma Announces the Registration of Sitavig® in European Countries
12/21/2012 9:06:17 AM
More...
|
BioAlliance Pharma: First Meeting of the DSMB of the ReLive Trial and Continuation Without Modification of the Phase III Clinical Trial With Livatag® in Primary Liver Cancer
12/20/2012 8:58:14 AM
More...
|
BioAlliance Pharma: First Meeting of the DSMB of the ReLive Trial and Continuation Without Modification of the Phase III Clinical Trial With Livatag® in Primary Liver Cancer
12/6/2012 10:25:26 AM
More...
|
|